UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-42004

 

NEWGENIVF GROUP LIMITED

(Exact name of registrant as specified in its charter)

 

36/39-36/40, 13th Floor, PS Tower

Sukhumvit 21 Road (Asoke)

Khlong Toei Nuea Sub-district

Watthana District, Bangkok 10110

Thailand

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

 

EXPLANATORY NOTE

 

Update on Non-Affiliate Shares and Outstanding Convertible Notes

 

NewGenIvf Group Limited (the “Company”) is furnishing the following information regarding its free-trading Class A ordinary shares and outstanding convertible notes as of the dates indicated below.

 

1. Non-Affiliate Shares – Continental Stock Transfer Report

 

According to the Continental Stock Transfer & Trust Company report for NewGenIvf Group Limited (CUSIP G6544E162 / A610ORD), the total number of shares outstanding as of November 17, 2026:

 

●Class A Ordinary Shares: 2,790,883
   
●Class B Ordinary Shares: 9,136

 

Of these outstanding shares, 2,752,036 Class A Shares were held by non-affiliates.

 

2. Outstanding Convertible Notes

 

As of November 17, 2026, the Company has outstanding convertible notes with an aggregate principal amount of US$2,044,373. Of this amount, only US$323,812 (the notes that have been outstanding more than 180 days) is currently eligible for conversion. The remaining notes remain subject to escrow or Rule 144 restrictions and are not freely convertible at this time.

 

This information is being furnished solely for the convenience of investors and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 17, 2026

 

  NewGenIvf Group Limited
     
  By: /s/ Wing Fung Alfred Siu
  Name:  Wing Fung Alfred Siu
  Title: Chairman of the Board and Director

 

2